Imagine a cancer cell has a master engine called MYC that keeps it growing and resisting medicine, but this engine is shaped like a slippery knot that normal drugs can't grab. This project created a special 'mini-protein' that can actually grip and shut down that engine. It also uses AI to find a biological fingerprint that tells doctors exactly which patients will respond best to the treatment.
Pancreatic cancer has a survival rate of less than 10% over 5 years because the MYC protein, which drives tumor growth, has been considered 'undruggable' due to its structure and location.
A patented cell-penetrating mini-protein (OMO-103) and AI-driven companion diagnostic tests for patient stratification and response monitoring.
If you are a pharmaceutical company dealing with the lack of effective treatments for pancreatic cancer — this project developed OMO-103 that showed a 49% tumor volume reduction in a metastatic PDAC patient. This provides a first-in-class asset to fill a critical gap in the oncology pipeline.
If you are a biotech company dealing with poor patient stratification in clinical trials — this project developed machine learning-enabled biomarker signatures that allow for real-time response monitoring. This ensures the right patients receive the therapy, increasing trial success rates.
If you are a CDMO dealing with the need for high-scale mini-protein production — this project is developing a commercial-ready manufacturing process to sustain the scale-up phase. This creates a blueprint for producing complex cell-penetrating proteins at scale.
The drug OMO-103 is patented. Peptomyc's explicit business goal is to reach a licensing agreement with a pharmaceutical company for its further development and commercialization.
The project aims to develop a commercial-scale compatible manufacturing process to sustain the scale-up phase of the product.
Based on available project data, specific pricing or cost-per-dose information is not provided.
The next step is to perform a Phase 1b clinical trial in 1st-line pancreatic ductal adenocarcinoma (PDAC) patients to assess safety and efficacy in combination with the standard of care.
OMO-103 is designed to foster synergy with personalized therapies and will be tested in combination with the standard of care for PDAC.
The project is led by a single Spanish SME, Peptomyc SL, with a 100% industry ratio. This lean structure indicates a highly focused, agile development approach typical of specialized biotech startups aiming for a licensing exit rather than a large academic consortium.
Contact Peptomyc SL in Spain regarding OMO-103 licensing
Contact us to explore licensing opportunities for MYC-inhibitor technology.
